These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 15709899)

  • 41. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
    Onofrj M; Thomas A; Iacono D; Di Iorio A; Bonanni L
    Eur Neurol; 2001; 46(1):11-6. PubMed ID: 11455177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism.
    Jorga KM; Davis TL; Kurth MC; Saint-Hilaire MH; LeWitt PA; Fotteler B; Zürcher G; Rabbia M
    Clin Neuropharmacol; 2000; 23(2):98-105. PubMed ID: 10803800
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and tolerability of COMT inhibitors.
    Brooks DJ
    Neurology; 2004 Jan; 62(1 Suppl 1):S39-46. PubMed ID: 14718679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.
    Haasio K; Sopanen L; Vaalavirta L; Lindén IB; Heinonen EH
    J Neural Transm (Vienna); 2001; 108(1):79-91. PubMed ID: 11261749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical experience of tolcapone in advanced Parkinson's disease.
    Canesi M; Zecchinelli AL; Pezzoli G; Antonini A
    Neurol Sci; 2008 Dec; 29 Suppl 5():S380-2. PubMed ID: 19381768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.
    Lees AJ
    CNS Neurosci Ther; 2008; 14(1):83-93. PubMed ID: 18482101
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Entacapone in the management of Parkinson's disease.
    Henchcliffe C; Waters C
    Expert Opin Pharmacother; 2002 Jul; 3(7):957-63. PubMed ID: 12083995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.
    Waters C
    J Am Geriatr Soc; 2000 Jun; 48(6):692-8. PubMed ID: 10855610
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
    Gerlach M; Xiao AY; Kuhn W; Lehnfeld R; Waldmeier P; Sontag KH; Riederer P
    J Neural Transm (Vienna); 2001; 108(2):189-204. PubMed ID: 11314772
    [TBL] [Abstract][Full Text] [Related]  

  • 51. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
    Jorga KM; Nicholl DJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
    Jorga K; Banken L; Fotteler B; Snell P; Steimer JL
    Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group.
    Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S
    Neurology; 1997 Sep; 49(3):665-71. PubMed ID: 9305320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.
    Koller W; Lees A; Doder M; Hely M;
    Mov Disord; 2001 Sep; 16(5):858-66. PubMed ID: 11746615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
    Nyholm D; Johansson A; Lennernäs H; Askmark H
    Eur J Neurol; 2012 Jun; 19(6):820-6. PubMed ID: 22136163
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Henry C; Wilson JA
    Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299
    [No Abstract]   [Full Text] [Related]  

  • 59. Issues important for rational COMT inhibition.
    Dingemanse J
    Neurology; 2000; 55(11 Suppl 4):S24-7; discussion S28-32. PubMed ID: 11147507
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New options for treatment of Parkinson's disease.
    LeWitt PA
    Baillieres Clin Neurol; 1997 Apr; 6(1):109-23. PubMed ID: 9426871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.